[Click eStock] "Deepnoid Enters Remote Reading Market with Generative AI Solutions"

On the 12th, SK Securities stated that major countries are actively adopting medical artificial intelligence (AI), and predicted that Deepnoid will benefit from this trend.

Heo Seonjae, a researcher at SK Securities, explained, "The medical AI industry is divided into image interpretation, new drug development, and other healthcare businesses utilizing AI," adding, "This year, it would be good to focus on the image interpretation market, which has a large market size and is expected to monetize quickly."

He continued, "The Ministry of Food and Drug Safety (MFDS) announced the world's first 'Generative AI Medical Device Guidelines' on the 24th of last month," and added, "Starting as early as this year, the launch of generative AI solutions for medical use will lead to the full-scale blossoming of the AI-based image interpretation market."

Furthermore, he emphasized, "The domestic and international remote interpretation markets will grow rapidly due to bottlenecks in medical image processing and the resulting unmet medical needs of patients," and "The growth of the domestic remote interpretation market is expected to accelerate even more."

He expressed expectations, saying, "Deepnoid is entering the remote interpretation market through its generative AI solution ‘M4CXR’," and "It will be able to demonstrate the revenue-generating capability of medical AI technology."

Researcher Heo added, "Deepnoid can secure its own data and perform AI model fine-tuning," and “has submitted a clinical trial plan application to the MFDS and is expected to be introduced in medical settings by the end of this year.”